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Abstract
Background: Carvedilol is a non-selective, third-generation beta-blocker and is one of the cornerstones for treatment
for patients with heart failure and reduced ejection fraction (HFrEF). However, due to its short half-life,
immediate-release carvedilol (IR) needs to be prescribed twice a day. Recently, slow-release carvedilol (SR)
has been developed. The aim of this study is to evaluate whether carvedilol-SR is non-inferior to standard
carvedilol-IR in terms of its clinical efficacy in patients with HFrEF.
Methods/design: Patients with stable HFrEF will be randomly assigned in a 1:1 ratio to the carvedilol-SR
group (160 patients) and the carvedilol-IR group (160 patients). Patients aged≥ 20 years, with a left ventricular ejection
fraction≤ 40%, N-terminal pro B-natriuretic peptide (NT-proBNP)≥ 125 pg/ml or BNP≥ 35 pg/ml, who are clinically
stable and have no evidence of congestion or volume retention, will be eligible. After randomization, patients will be
followed up for 6 months. The primary endpoint is the change in NT-proBNP level from baseline to the study end. The
secondary endpoints include the proportion of patients with NT-proBNP increment > 10% from baseline, composite of
all-cause mortality and readmission, mortality rate, readmission rate, changes in blood pressure, quality of life,
and drug compliance.
Discussions: The SLOW-HF trial is a prospective, randomized, open-label, phase-IV, multicenter study to
evaluate the therapeutic efficacy of carvedilol-SR compared to carvedilol-IR in HFrEF patients. If carvedilol-SR
proves to be non-inferior to carvedilol-IR, a once-daily prescription of carvedilol may be recommended for
patients with HFrEF.
Trial registration: ClinicalTrials.gov, ID: NCT03209180. Registered on 6 July 2017.
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Background
Heart failure (HF) is a clinical syndrome characterized by
typical symptoms and signs that result from abnormal car-
diac structure or function [1]. It is globally present with an
increasing prevalence and is associated with high morbid-
ity and mortality [2, 3]. The current treatment of HF tar-
gets includes the prevention of acute decompensation and
improving the long-term survival of HF patients [4].
Neuro-humoral activation plays a crucial role in devel-
opment and progression of HF [5]. Beta-blockers reduce
the increased sympathetic tone in HF patients and have
been shown to improve the survival in patients with HF
and a reduced ejection fraction (HFrEF) [6–8]. Carve-
dilol is a non-selective beta-blocker which has been most
extensively studied in HF patients with mild-to-severe
left ventricular (LV) dysfunction [8, 9]. Carvedilol has
also shown additional mortality risk reduction in HFrEF
patients compared to metoprolol [10].
Current HF guidelines recommend the administration
of carvedilol twice daily [1, 11]. This is due to rapid ab-
sorption and metabolism of carvedilol whose plasma
concentration reaches a peak within 1–2 h after admin-
istration and shows an elimination half-life of 7–10 h
after peak concentration [12]. Although the drug com-
pliance of carvedilol was comparable between once- and
twice-daily dosing in one report [13]; however, there has
been a concern that regimen complexity is inversely as-
sociated with medication adherence and related to even
worse clinical outcomes in other studies and real-world
clinical practice [14–16].
In the “Assessment of clinical effect and treatment
quality of immediate-release carvedilol-IR versus
SLOW-release carvedilol-SR in Heart Failure patients
(SLOW-HF): a prospective, randomized, open-label,
multicenter study,” we aim to evaluate the clinical effica-
cies of immediate-release carvedilol (IR) and slow-
release carvedilol (SR) forms of carvedilol in Asian
HFrEF patients.
Methods/design
Overview
The study flow is presented in Fig. 1. This trial is a pro-
spective, randomized, open-label, phase-IV, multicenter
trial to evaluate the efficacy of carvedilol-SR. The aim of
this study is to evaluate whether carvedilol-SR is non-
inferior to standard carvedilol-IR in terms of its clinical
efficacy in patients with HFrEF. The protocol of this trial
has been registered at ClinicalTrials.gov (registration
number: NCT03209180). The protocol follows the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) Checklist (Additional file 1).
Fig. 1 Study flow chart. BNP B-type natriuretic peptide, HFrEF heart failure with reduced ejection fraction, IR immediate-release, LVEF left ventricular
ejection fraction, NT-proBNP N-terminal B-type natriuretic peptide, SR slow-release
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Study population
Patients who are at aged 20 years or older and with a
confirmed diagnosis of HFrEF (left ventricular ejection
fraction (LVEF) ≤ 40%) within the pre-analytical 6
months will be included in this study. Transthoracic
echocardiography was operated at each institute accord-
ing to the recommendations of the American Society of
Echocardiography using commercially available systems
[17]. In addition, the patients should be clinically stable
without evidence of congestion and fluid retention, and
have an increased level of N-terminal B-type natriuretic
peptide (NT-proBNP) or BNP. Blood sampling and tests
including NT-proBNP were conducted by laboratories at
each participating institute which were certified by The
Korean Association of Quality Assurance for Clinical La-
boratory. After enrollment, measurement of NT-proBNP
will be performed with an electro-chemiluminescence
immunoassay method using cobas® 8000 (Roche Diag-
nostics, Mannheim, Germany) in a central laboratory.
Patients will be enrolled at 13 tertiary referral centers in
the Republic of Korea. Patients will be excluded if
they have any of followings: low blood pressure (sit-
ting systolic blood pressure < 90 mmHg), bradycardia
(resting heart rate < 50 beats/min), ischemic heart dis-
ease (unstable angina, myocardial infarction) within
1 month, severe cerebrovascular accident, respiratory
diseases with bronchospasm, and peripheral vascular
diseases. The detailed inclusion and exclusion criteria
are listed in Table 1.
Endpoints
The primary endpoint is the change in N-terminal pro
B-natriuretic peptide (NT-proBNP) level from baseline
to 6 months after randomization. The secondary end-
points include the proportion of patients with NT-
proBNP increment > 10% from baseline, composite of
all-cause mortality and readmission, mortality rate, re-
admission rate, change in systolic and diastolic blood
pressure at sitting position, control rate and response
rate of blood pressure among patients with elevated
blood pressure at baseline, quality of life assessed by the
Minnesota Living with Heart Failure Questionnaire and
Visual Analog Scale, and drug compliance. Table 2 dem-
onstrates the detailed endpoints.
Randomization
Subjects who meet the inclusion and exclusion criteria
will be randomly assigned to the carvedilol-SR or
carvedilol-IR groups, respectively. The randomization
table will be generated by an independent statistician
using the SAS system’s randomization program. Re-
stricted block randomization is applied in order to en-
sure that the subjects are assigned to each group in a
balanced manner. At this time, the size of the block will
Table 1 Inclusion and exclusion criteria
Inclusion criteria
1 Men or women aged 20 years or older
2 Confirmed left ventricular ejection fraction ≤ 40% by
echocardiography within the pre-analytical 6 months
3 NT-proBNP level ≥ 125 pg/ml or BNP level ≥ 35 pg/ml within the
pre-analytical 3 months
4 Clinically stable patient without evidence of congestion or
extracellular fluid retention
5 Patients providing written informed consent
Exclusion criteria
1 Systolic blood pressure in a sitting position < 90 mmHg or resting
heart rate < 50 beats/min at screening
2 Patient has a contraindication to beta-blockers
3 Patient who are expected to take another beta-blocker after
randomization
4 Cardiovascular diseases;
Ischemic heart disease (unstable angina, myocardial infarction)
within 1 month
Hypertrophic cardiomyopathy
Cor pulmonale
Hemodynamically significant stenosis of the aorta, aortic valve, or
mitral valve
Acute myocardial infarction with complications
5 Severe cerebrovascular accident (for example, ischemic stroke or
cerebral hemorrhage) within the pre-analytical within 6 months
6 Glottic edema, allergic rhinitis, respiratory diseases with bronchospasm
such as asthma and chronic obstructive lung disease
7 Peripheral vascular disease (for example, Raynaud’s syndrome,
intermittent claudication)
8 Patients who needs vasopressor support due to prominent volume
retention/overload
9 Moderate-to-severe retinopathy (for example, retinal hemorrhage, v
isual disturbance, retinal microaneurysm within 6 months)
10 Impaired renal function (serum creatinine ≥ 2.5 mg/dL) or hepatic
function (AST or ALT ≥ 3 × ULM)
11 Patients in a clinical status that can significantly influence absorption,
distribution, metabolism, and secretion of drugs for clinical trials:
History of major gastrointestinal surgery, such as gastrectomy or
gastric bypass surgery
Inflammatory bowel disease within 12 months
Current gastric ulcer, pancreatic function abnormality including
pancreatitis, gastrointestinal/rectal bleeding which requires treatment
Current urologic stenosis or obstruction which requires treatment
12 Confirmed or suspected drug/alcohol abuse within 6 months
13 Pregnant or lactating women, suspected pregnant women or
lactating women
14 Chronic inflammatory diseases which require anti-inflammatory
treatment
15 Hypersensitivity to carvedilol
16 Malignant disease including lymphoma and leukemia within 5 years
17 Patients who were prescribed other medication for any other clinical trials
within the pre-analytical 28 days
18 Patients who are expected to have prolonged hospital stay due to
other medical problems other than chronic heart failure (for example,
femoral neck fracture)
19 Patients who are considered inappropriate by researchers to
participate in the clinical trial
ALT alanine transaminase, AST aspartate transaminase, NT-proBNP N-terminal
pro B-type natriuretic peptide, ULM upper limit of meta-stability
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be set by a multiple of 2 (for example, 2, 4, 68, etc.)
and it will be implemented using the uniform
random-number generator in SAS version 9.2. Web-
based randomization will be used and all investigators
will be masked to this process until the allocation has
been determined.
Carvedilol treatment protocol
In this study, we will use carvedilol (trade name:
Dilatrend®) which is manufactured and distributed by
Chong Kun Dang Pharmaceutical Corporation in the
Republic of Korea. After randomization, patients will
receive either carvedilol-IR twice a day or carvedilol-
SR once a day for 6 months. Patients in the
carvedilol-IR group will receive carvedilol-IR 3.125-
mg, 6.25-mg, 12.5-mg, and 25-mg tablets twice a day,
while patients in the carvedilol-SR group will receive
carvedilol-SR 8-mg, 16-mg, 32-mg, and 64-mg tablets
once a day. If the patients were taking beta-blockers
other than carvedilol, their dose will be calculated
into the equivalent dose of carvedilol (Table 3). The
dose of carvedilol can be up-titrated at the discretion
of the treating physician.
Prohibited drugs during the clinical trial
To avoid drug-drug interactions that may exert con-
founding effects, drugs with pharmacodynamic and
pharmacokinetic interference will be prohibited during
the clinical trial (Table 4).
Clinical follow-up
All patients will be clinically followed up at 2, 4, and
6 months after randomization at each participating cen-
ter. Each clinic visit comprises history taking, physical
examination, laboratory tests, and a 12-lead electrocar-
diograph (ECG). Drug compliance, adverse effects, and
additional concomitant drugs will also be checked. Any
unscheduled visit will be recorded. The detailed process
is described in Table 5.
Evaluation of drug compliance
Drug compliance will be assessed by “pill count,” by com-
paring the number of doses remaining with the number of
doses that should remain. All patients will be educated to
bring the remaining tablets of carvedilol-IR or -SR to each
scheduled visits during the clinical follow-up period.
Examiners will count the number of returned pills and
calculate the drug compliance as follows:
Drug compliance ¼
number of pills dispensed−number of pills returned
number of pills dispensed
If any discrepancy is present, examiners should record
the reason for the difference. Overall medication compli-
ance should be at least 80% or more during the trial.
Subjects who do not satisfy this criterion will be ex-
cluded from the per-protocol (PP) analysis.
Statistical analysis
Sample size calculation
The aim of the study is to evaluate whether the clinical
efficacy of carvedilol-SR is non-inferior to carvedilol-IR
in terms of NT-proBNP reduction in stable Asian HFrEF
patients. Therefore, the sample size was calculated based
on the primary endpoint, i.e., the change in NT-proBNP
level from baseline to 6 months. Olsson et al. [18]
showed a decrease in NT-proBNP level by 334.5 ±
311.3 pg/ml in patients with chronic HF and receiving
carvedilol. We established a non-inferiority margin of
110 pg/ml, which corresponds to 33.3% of the mean
change. With an estimated dropout rate of 10%, a total
of 320 patients (160 patients in each group) would be
necessary to provide a power of 85% with a one-sided
alpha of 2.5%. This will provide 95% power to demon-
strate the non-inferiority of carvedilol-SR once a day
compared to carvedilol-IR twice a day (Fig. 2).
Statistical analysis
Data will be presented as numbers and frequencies for
categorical variables, and as means ± standard deviations
or median with interquartile range for continuous vari-
ables. For comparisons between the carvedilol-IR group
and carvedilol-SR group, the χ2 test or Fisher’s exact test
will be used for categorical variables, and the unpaired
Student t test will be used for continuous variables, as
appropriate. Fisher’s exact test will be used when the
expected frequencies are less than 5. The change in NT-
proBNP level from baseline to 6 months after
randomization will be analyzed with the paired t test. In
addition, analysis of covariance (ANCOVA) will be also
Table 2 Primary and secondary endpoints
Endpoint details
Primary
endpoint
Change in of NT-proBNP level from baseline to 6 months
after randomization
Secondary
endpoints
The frequency of NT-proBNP increment > 10% from
baseline
Composite of all-cause mortality and readmission
All-cause mortality rate and readmission rate
Change in systolic/diastolic blood pressure at
sitting position, control/response rate of
blood pressure
Quality of life assessment by the MLHFQ, Visual
Analog Scale
Drug compliance
MLHFQ Minnesota Living with Heart Failure Questionnaire, NT-proBNP N-terminal
pro B-type natriuretic peptide
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conducted to analyze the change of NT-proBNP. The
outcomes of chronological trend, such as mortality
and readmission rate, will be assessed using Kaplan-
Meier estimates. The log-rank test will be used to
compare differences in clinical outcomes between the
groups. A multivariable Cox proportional hazard re-
gression model will be used to adjust for significant
covariates. The data will be primarily analyzed ac-
cording to the intention-to-treat rule including all
randomized subjects. We also plan a PP analysis for
patients with drug compliance of 80% or less. One-
sided p values < 0.05 will be considered statistically
significant. The analyses will be performed by a pro-
fessional statistician.
Trial organization
Executive Committee
The Executive Committee will be composed of the
study chairperson and the principal investigators of
the investigating centers. This committee will approve
the final trial design and protocol issued to the Data
and Safety Monitoring Board (DSMB) and the clinical
sites. This committee will also be responsible for
reviewing the final results, determining the methods
of presentation and publication, and the selection of
secondary projects and publications by members of
the Steering Committee.
Data Safety Monitoring Board (DSMB)
An independent DSMB will be composed of cardiolo-
gists and a biostatistician, all of whom did not partici-
pate in the trial, following the applicable regulatory
guidelines. The DSMB will review the safety data
from this study and will make recommendations
based on safety analyses of unanticipated device ef-
fects (UADEs), serious adverse events (SAEs), protocol
deviations, and follow-up reports. In addition to the
scheduled DSMB meetings (which will be determined
prior to the initiation of the study) the board will
convene a meeting at any time if safety problems be-
come an issue. The DSMB is responsible for recom-
mending to the Executive Committee to modify or
stop the study if there are any safety or compliance
issues. However, the final decision regarding study
modifications will rest with the Executive Committee.
Cumulative safety data will be reported to the DSMB
and will be reviewed on an ongoing basis throughout
enrollment and follow-up to ensure patient safety.
Every effort will be made to allow the DSMB to
conduct an unbiased review of the patients’ safety in-
formation. All DSMB reports will be made available
to the appropriate agencies upon request but other-
wise will remain strictly confidential. Prior to the
DSMB’s first review of the data, the DSMB charter
will be drafted. This plan defines the stopping rules
Table 3 Equivalent dose of carvedilol with other beta-blockers
Dose
Carvedilol IR 3.125 mg bid 6.25 mg bid 12.5 mg bid 25 mg bid
Carvedilol SR 8 mg qd 16 mg bid 32 mg bid 64 mg qd
Bisoprolol 1.25 mg qd 2.5 mg qd 5 mg qd 10 mg qd
Nebivolol 1.25 mg qd 2.5 mg qd 5 mg qd 10 mg qd
Metoprolol succinate 25 mg qd 50 mg qd 100 mg qd 200 mg qd
bid twice daily, IR immediate-release, qd four times daily, SR slow-release
Table 4 Contraindicated drugs during clinical trial
Contraindication details
1 Other beta-blockers except the study medication
2 Steroid medication (ACTH or corticosteroid). Locally applied drugs are allowed.
3 Non-steroidal anti-inflammatory drugs. They are allowed only for shor term use (≤7 days) according to the examiner’s decision, while their usage is
absolutely prohibited 3 days before the scheduled visits. Low-dose aspirin (30 to 300 mg daily) for cardiovascular diseases is allowed.
4 Estrogen medications. If necessary, low-dose hormonal therapy can be continued for therapeutic purpose at the same dose during the study period
5 Sympathomimetic drugs such as catecholamines
6 Anti-psychotics:
MAO inhibitors, anti-depressants (tri- and tetra-cyclic classes, selective serotonin reuptake inhibitors including lithium)
Sedatives and anti-anxiolytics (benzodiazepines and their antagonists, barbiturates, hypnotics such as zolpidem) can be intermittently used according to the
physician's decision, while their usage is absolutely prohibited 7 days before the scheduled visits
7 Immunosuppressants
8 Thyroid hormones. If necessary, thyroid hormonal therapy can be prescribed for therapeutic purpose at the same dose during the study period
ACTH adrenocorticotropic hormone, MAO monoamine oxidase
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for stopping the trial for safety. The first meeting of
the DSMB will be requested for discussion of the
protocol and an understanding of all the protocol
elements. The DSMB will develop a consensus under-
standing of all trial endpoints and definitions used in
the event adjudication process.
Clinical Event Adjudication Committee (CEAC)
The Clinical Events Adjudication Committee (CEAC)
consists of cardiologists who do not participate in this
study. The CEAC has responsibility to develop specific
criteria used for the categorization of clinical events and
clinical endpoints in the study, which are based on
protocol. At the onset of the trial, the CEAC establishes
regulations mentioning the minimum amount of data
required and the algorithm followed in order to classify
a clinical event. All members of the CEAC are blinded
to the primary results of the study and meet regularly to
review and adjudicate all clinical events in which the
required minimum data is available. The CEAC also
reviews and rules on all deaths that may occur during
the trial.
Table 5 Trial process chart
Visit Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Status
Period
Screening
− 2 to 0 week
Baseline
0 months
2 months
(± 4 days)
4 months
(± 14 days)
6 months
(± 14 days)
Inclusion/exclusion criteria •
Informed consent •
Demographic data •
Past medical historya •
Randomization •
Physical examination • • • • •
Vital signs • • • • •
Height and weightb • • • • •
Blood analysisc • • •
Urinalysisd • • •
Pregnancy teste • • •
Chest x-rayf •
12-lead electrocardiographg • •
Echocardiographyh • • •
Concomitant medication • • • • •
Adverse events • • • •
Patient’s compliance • • •
Questionnaire for quality of life • •
aThe history of diseases, medications, and operations will be recorded
bCheck weight only after visit 2
cCBC: WBC with differential count, hemoglobin, hematocrit, platelets; chemistry: albumin, total protein, triglycerides, high-density lipoprotein-cholesterol, low-density
lipoprotein-cholesterol, blood urea nitrogen, serum creatinine, uric acid, total bilirubin, AST, ALT, ALP, NT-proBNP, hs-CRP; electrolytes: Na, K, Ca, Cl, P
dSpecific gravity, pH, albumin (protein), glucose, blood (occult blood), urobilinogen, ketones
eWomen of child-bearing age
f,gExamination at visit 6 can be optionally performed according to the examiner’s decision
hFollow-up echocardiograph, if available
Fig. 2 Possible outcomes of the study. Δ stands for the
non-inferiority margin
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Data coordination and site management
Data coordination and site management services are per-
formed by the Clinical Trials Center at Seoul National
University Bundang Hospital.
Ethical approval
This clinical trial was approved by the Institutional Review
Board or Ethics Committee at each of the 13 participating
hospitals; they are: Seoul National University Bundang
Hospital, Seoul National University Hospital, Yonsei Uni-
versity Severance Hospital, Wonju Severance Christian
Hospital, Samsung Medical Center, Sejong General Hos-
pital, Ajou University Hospital, Boramae Medical Center,
Hallym University Medical Center, Korea University Guro
Hospital, Korea University Anam Hospital, Seoul Medical
Center, and Asan Medical Center. The investigation will
conform to the principles outlined in the Declaration of
Helsinki. The study protocol has been registered at Clini-
calTrials.gov (NCT03209180). All authors are responsible
for the study design, data acquisition, data analysis, manu-
script writing and editing.
Discussion
After an initial cardiac injury, there is an increase in
neuro-humoral activity, i.e., the sympathetic nervous sys-
tem and renin-angiotensin-aldosterone system [5]. This
response can temporarily increase the myocardial con-
tractility [19]; however, sustained over-activation can
lead to the development and progression of HF [20].
Thus, angiotensin-converting enzyme inhibitors/angio-
tensin-receptor blockers and beta-blockers have been
used to attenuate the neuro-humoral over-activation and
have been shown to improve the prognosis of patients
with HFrEF. Unlike to renin-angiotensin system blockers
(RAS blockers), only four beta-blockers, i.e., carvedilol,
metoprolol succinate, bisoprolol, and nebivolol, have
demonstrated a beneficial effect. For example, bucindolol
and propranolol failed to show any clinical benefit, sug-
gesting that the beneficiary effect of beta-blockers is not
“a class effect” but a substrate-specific effect [6, 7, 21–23].
Therefore, the current clinical practice guidelines for man-
aging HF patients provide detailed information on the
drug name and target dose for each agent [1, 11].
Carvedilol has been extensively evaluated in HFrEF
patients with mild-to-severe LV dysfunction [8, 9, 24] and
has demonstrated remarkable efficacy in improving clinical
outcomes [10]. Unlike bisoprolol and metoprolol succinate,
carvedilol has a short elimination half-life, so that it needs
to be administrated twice a day [12]. Many HF patients
have advanced age and have multiple comorbidities, so that
they take multiple drugs [2, 25]. A complex medication
regimen causes reduced drug compliance and, conse-
quently, can lead to worse clinical outcomes [14, 16, 26]. In
addition, the high drug adherence observed in well-
controlled clinical trials may differ from that in real-
world clinical practice. To increase the drug compli-
ance of carvedilol-IR, longer-acting carvedilol-SR has
been developed.
Carvedilol-SR meets the basic criteria for a controlled
release agent: (1) it maintains an effective plasma
concentration throughout the day and (2) does not ex-
ceed the critical value above which side effects often de-
velop [27]. In addition, regarding the pharmacokinetic
profile, carvedilol-SR once daily was similar to that for
carvedilol-IR given twice daily [27].
The SLOW-HF study is a randomized, open-label.
phase-IV clinical trial that investigates the clinical
benefit and safety of carvedilol-SR compared to
carvedilol-IR in patients with HFrEF. If carvedilol-SR
is not inferior to carvedilol-IR in terms of clinical
efficacy and safety, it would be a useful therapeutic
option to improve medication complexity and compli-
ance in managing HFrEF patients.
Study limitations
There are several limitations. First, the primary endpoint
of our study is the change in NT-proBNP level from
baseline to the study end. Although NT-proBNP is a
well-validated marker for risk stratification and used as a
surrogate marker for clinical outcomes, clinical end-
points, such as mortality and rehospitalization for wors-
ening HF, would be more definitive. Second, there exists
a possibility that patients with more advanced HF may
be under-represented in this study because they often
have fluid volume retention. However, similar findings
have been observed in other clinical trials which investi-
gated the effect of beta-blocker management in HF
patients [6, 7, 10, 21]. Finally, this is an open-label study.
Trial status
The trial is currently in the recruitment phase (recruit-
ment began on 27 October 2016 and is expected to fin-
ish on 31 December 2018).
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